Amgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down by the regulator because of safety concerns. The agency approved Evenity (romosozumab ...

Amgen and UCB have resubmitted their application for US approval of Evenity as an osteoporosis treatment, hoping that the additional data they have provided will help overcome the FDA’s previous ...

Is the Evenity Market Set to Witness Substantial Growth? The Evenity market has experienced steady expansion in recent years, demonstrating a strong historical compound annual growth rate (HCAGR ...